SCHEMBL15035141

SCHEMBL15035141

CCn1c(=O)c(-c2ccc(-c3ccccc3F)cc2Cl)cc2cnc(Nc3ccc(CCN(C)C)cc3)nc21

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 3/20 0.53
EGFR P00533 2/20 0.53
STK4 Q13043 4/20 0.52
STK3 Q13188 4/20 0.52
SIK2 Q9H0K1 4/20 0.52
STK26 Q9P289 4/20 0.52
STK24 Q9Y6E0 4/20 0.52
PAK1 Q13153 4/20 0.52
PKN1 Q16512 4/20 0.52
PAK4 O96013 3/20 0.52
PAK3 O75914 3/20 0.52
PAK2 Q13177 3/20 0.52
LIMK1 P53667 1/20 0.52
LIMK2 P53671 1/20 0.52
RIPK2 O43353 3/20 0.49
ACVR1 Q04771 3/20 0.49
NOD2 Q9HC29 3/20 0.49
WEE1 P30291 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15035181 0.93 RIPK2 (0.56) FGFR1EGFRSTK4STK3SIK2
SCHEMBL14824684 0.92 FGFR1 (0.51) FGFR1EGFRSTK4STK3SIK2
SCHEMBL14824685 0.90 STK4 (0.52) FGFR1EGFRSTK4STK3SIK2
SCHEMBL15035139 0.89 STK3 (0.53) FGFR1EGFRSTK4STK3SIK2
SCHEMBL14824765 0.87 FGFR1 (0.55) FGFR1EGFRSTK4STK3SIK2
SCHEMBL14824683 0.86 STK4 (0.53) FGFR1EGFRSTK4STK3SIK2
SCHEMBL14824829 0.85 FGFR1 (0.55) FGFR1EGFRSTK4STK3SIK2
SCHEMBL15035179 0.85 RIPK2 (0.57) FGFR1EGFRSTK4STK3SIK2
SCHEMBL14824843 0.84 PAK1 (0.56) FGFR1EGFRSTK4STK3SIK2
SCHEMBL15030331 0.84 PKN1 (0.71) FGFR1EGFRSTK4STK3SIK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER AFRAXIS, INC. (US) 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER PAK5, PAK2, PAK6 FGFR1 1919/4885EGFR 737/4885STK4 272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.